Burst Diagnostics

Burst Diagnostics, founded in 2020 and based in Fort Collins, Colorado, is a medical technology company that develops point-of-care and at-home diagnostic solutions. The company’s core technology is the Capillary-flow Driven Immunoassay (CaDI) platform, which is designed to perform complex laboratory-grade enzyme-linked immunosorbent assays (ELISAs) within a compact, cost-effective cartridge. By utilizing capillary-flow based microfluidics to manage fluid movement without pumps, the platform provides rapid, sensitive, and quantitative results. This technology aims to overcome the limitations of traditional lateral flow assays, which often lack the sensitivity and quantitative capabilities required for specific medical diagnostics.

The company focuses on expanding access to high-quality testing by enabling decentralized, rapid results in clinical or at-home settings. Burst Diagnostics’ work includes developing multiplexed assays for hormone monitoring, such as estradiol and progesterone for perimenopause and menopause management, as well as testing for infectious diseases like Strep A and COVID-19. Supported by NIH research grants and partnerships with organizations like Innosphere Ventures and Zymo Research, the company provides custom assay development services and is building a patent portfolio to advance its diagnostic platform. Their work addresses the need for low-cost, accurate, and user-friendly testing alternatives to centralized laboratory systems.